Effects of a monthly injectable steroidal contraceptive, Mesigyna, on menstrual pattern, lipoproteins, and coagulation parameters

Basit Öğe Kaydı
dc.contributor.authorTiras, M.B.
dc.contributor.authorNoyan, V.
dc.contributor.authorFener, N.
dc.contributor.authorGuner, H.
dc.contributor.authorYildirim, M.
dc.contributor.authorDarney, P.D.
dc.date.accessioned2020-06-25T17:34:52Z
dc.date.available2020-06-25T17:34:52Z
dc.date.issued2001
dc.departmentKırıkkale Üniversitesi
dc.description.abstractThe objective of this study was to determine the effects of a once-monthly injectable contraceptive (Mesigyna) on menstrual pattern, lipoproteins, and coagulation parameters. Thirty-six women aged 18-35 years requesting monthly injectable contraception were included. Before injecting estradiol valerate 5 mg and norethisterone enanthate 50 mg, coagulation, lipoprotein, and liver function parameters were determined. After the 3- and 6-month injections, the same coagulation and serum lipid measurements and liver function tests were repeated, and women were questioned about their menstrual patterns and side effects. Thirty women who completed 6 months were evaluated. At the end of 3 months, two-thirds of the 30 women had normal menstrual patterns; at the end of 6 months, 80% of the women had normal menses. Serum LDL, total cholesterol, and triglyceride levels did not change significantly, while HDL and VLDL decreased significantly (p = 0.032 and p = 0.039, respectively) at 6 months. PT and aPTT measures did not change at the end of 6 months, while fibrinogen levels were significantly lower (p = 0.013). Serum total bilirubin levels increased (p = 0.022) and albumin levels decreased (p = 0.022) at the end of 6 months. Mesigyna was well tolerated and side effects and menstrual abnormalities were acceptable. There were no clinically significant changes in lipoprotein, coagulation, or hepatic parameters. (C) 2001 Elsevier Science Inc. All rights reserved.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1016/S0010-7824(01)00190-1
dc.identifier.endpage153en_US
dc.identifier.issn0010-7824
dc.identifier.issue3en_US
dc.identifier.pmid11368988
dc.identifier.scopus2-s2.0-0035013307
dc.identifier.scopusqualityQ2
dc.identifier.startpage151en_US
dc.identifier.urihttps://doi.org/10.1016/S0010-7824(01)00190-1
dc.identifier.urihttps://hdl.handle.net/20.500.12587/2935
dc.identifier.volume63en_US
dc.identifier.wosWOS:000168767700007
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Incen_US
dc.relation.ispartofContraception
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMesigynaen_US
dc.subjectmonthly injectable contraceptionen_US
dc.subjectmenstrual patternen_US
dc.subjectlipid profileen_US
dc.subjectcoagulation systemen_US
dc.titleEffects of a monthly injectable steroidal contraceptive, Mesigyna, on menstrual pattern, lipoproteins, and coagulation parametersen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Effects of a monthly injectable steroidal contraceptive, Mesigyna, on menstrual pattern, lipoproteins, and coagulation parameters.pdf
Boyut:
44.64 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu